- Home
- BWG vs FENC Comparison
BWG vs FENC Comparison
Compare BWG & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWG
- FENC
- Stock Information
- Founded
- BWG 2012
- FENC 1996
- Country
- BWG United States
- FENC United States
- Employees
- BWG N/A
- FENC N/A
- Industry
- BWG Finance/Investors Services
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BWG Finance
- FENC Health Care
- Exchange
- BWG Nasdaq
- FENC Nasdaq
- Market Cap
- BWG 140.2M
- FENC 156.9M
- IPO Year
- BWG N/A
- FENC 2001
- Fundamental
- Price
- BWG $8.35
- FENC $6.09
- Analyst Decision
- BWG
- FENC Strong Buy
- Analyst Count
- BWG 0
- FENC 2
- Target Price
- BWG N/A
- FENC $14.00
- AVG Volume (30 Days)
- BWG 53.8K
- FENC 120.6K
- Earning Date
- BWG 01-01-0001
- FENC 03-10-2025
- Dividend Yield
- BWG 11.37%
- FENC N/A
- EPS Growth
- BWG N/A
- FENC N/A
- EPS
- BWG N/A
- FENC N/A
- Revenue
- BWG N/A
- FENC $47,538,000.00
- Revenue This Year
- BWG N/A
- FENC $28.99
- Revenue Next Year
- BWG N/A
- FENC $63.21
- P/E Ratio
- BWG N/A
- FENC N/A
- Revenue Growth
- BWG N/A
- FENC 123.69
- 52 Week Low
- BWG $6.86
- FENC $3.96
- 52 Week High
- BWG $8.65
- FENC $11.29
- Technical
- Relative Strength Index (RSI)
- BWG 43.46
- FENC 39.43
- Support Level
- BWG $8.39
- FENC $6.25
- Resistance Level
- BWG $8.45
- FENC $6.90
- Average True Range (ATR)
- BWG 0.09
- FENC 0.34
- MACD
- BWG -0.02
- FENC -0.04
- Stochastic Oscillator
- BWG 23.21
- FENC 19.82
About BWG BrandywineGLOBAL Global Income Opportunities Fund Inc.
BrandywineGLOBAL - Global Income Opportunities Fund Inc is a non-diversified, closed-end management investment company. The primary investment objective is to provide current income. The secondary investment objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing, under normal market conditions, at least 80% of its assets in world-wide fixed-income securities.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.